Brokerage firm B. Riley Downgrades its rating on Heska Corp(NASDAQ:HSKA). In a research note issued to the investors, the brokerage major Raises the price-target to $53.00 per share. The shares have been rated Neutral. Previously, the analysts had a Buy rating on the shares. The rating by B. Riley was issued on Sep 21, 2016.
In a different note, On Aug 4, 2016, Gabelli & Co. said it Downgrades its rating on Heska Corp. The shares have been rated ‘Hold’ by the firm.
Heska Corp (HSKA) made into the market gainers list on Tuesdays trading session with the shares advancing 1.49% or 0.82 points. Due to strong positive momentum, the stock ended at $55.68, which is also near the day’s high of $56.14. The stock began the session at $55.41 and the volume stood at 1,16,810 shares. The 52-week high of the shares is $57.41 and the 52 week low is $26.255. The company has a current market capitalization of $383 M and it has 68,75,256 shares in outstanding.
Heska Corp(HSKA) last announced its earnings results on Aug 3, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $29.96M. Analysts had an estimated revenue of $28.47M. Earnings per share were $0.35. Analysts had estimated an EPS of $0.18.
Several Insider Transactions has been reported to the SEC. On Sep 1, 2016, Jason A Napolitano (COO, CFO, EVP and Secretary) sold 5,000 shares at $52.54 per share price.Also, On Aug 30, 2016, Kevin S. Wilson (CEO and President) sold 20,000 shares at $51.78 per share price.On Aug 10, 2016, Steve Asakowicz (EVP, Comp. Animal Health Sales) sold 4,698 shares at $52.55 per share price, according to the Form-4 filing with the securities and exchange commission.
Heska Corporation develops manufactures markets sells and supports veterinary products. The Company is focused on the canine and feline companion animal health markets. The Company operates in two segments: Core Companion Animal Health and Other Vaccines Pharmaceuticals and Products. The Core Companion Animal Health segment (CCA) includes primarily for canine and feline use blood testing instruments and supplies digital imaging products software and services and single use products and services such as heartworm diagnostic tests heartworm preventive products allergy immunotherapy products and allergy testing. The Other Vaccines Pharmaceuticals and Products segment (OVP) includes private label vaccine and pharmaceutical production primarily for cattle but also for other animals including small mammals.